Search clinical trials for: Clopidogrel and Dexlansoprazole

Total 269096 results

Takeda

Completed

A Study of the Effects of Multiple Doses of Dexlansoprazole, Lansoprazole, Omeprazole or Esomeprazole on the Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Participants.

Healthy

United States
Taipei Veterans General Hospital, Taiwan

Unknown

Comparison of the Efficiency of Two Different PPI Formula in Atypical GERD

Compare the Response Rate of Atypical GERD After PPI Therapy

Taiwan
Takeda

Completed

A Study to Compare the Bioavailability (BA) of Dexlansoprazole Delayed-release Capsules

Healthy Volunteers

United States
Takeda

Completed

Bioequivalence Study of Dexlansoprazole Capsules From Two Manufacturing Plants

Healthy Volunteers

United States
AstraZeneca

Completed

Study Evaluating Effect of Esomeprazole, Omeprazole or Lansoprazole on the Pharmacodynamics (PD) and Pharmacokinetics (PK) of Clopidogrel

Healthy

United States
Soonchunhyang University Hospital

Unknown

Dexlansoprazole MR in Nonerosive Reflux Disease

Nonerosive Reflux Disease

Korea, Republic of
Takeda

Completed

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

Bioavailability

United States
University Hospital, Toulouse

Completed

TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement (TIRATROP)

Atherosclerosis

France
Takeda

Terminated

Effect of Dexlansoprazole 60 mg QD and 60 mg BID on Recurrence of Intestinal Metaplasia in Subjects Who Have Achieved Complete Eradication of Barrett's Esophagus With Radiofrequency Ablation

Barrett's Esophagus

United States
First Affiliated Hospital of Zhejiang University
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Completed

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults (Part 1)

Safety Issues
Northwestern University
Washington University School of Medicine; Vanderbilt University

Completed

Effectiveness of Physiologic Testing in PPI Non-Responders

Gastro Esophageal Reflux

United States
Mayo Clinic

Withdrawn

Predictors of Proton Pump Inhibitor (PPI) Response in Eosinophilic Esophagitis

Gastroesophageal Reflux Disease | Dysphagia | Eosinophilic Esophagitis
Takeda

Completed

Safety and Quality of Life Study of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Takeda

Completed

Pharmacokinetic and Safety of Dexlansoprazole in Adolescents With Gastroesophageal Reflux Disease

Gastroesophageal Reflux

United States
Indiana University

Terminated

The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

Laryngopharyngeal Reflux

United States
Mayo Clinic

Completed

Does Intensive Acid Suppression Reduce Esophageal Inflammation and Recurrent Barrett's Esophagus Following Ablation?

Inflammation | Barrett's Esophagus

United States
Spital Limmattal Schlieren

Withdrawn

Dexlansoprazole Absorption and Marginal Ulceration After Gastric Bypass

Bariatric Surgery
American University of Beirut Medical Center
Takeda

Completed

An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan

GERD | Proton Pump Inhibitor

Lebanon
First Affiliated Hospital of Zhejiang University
Jiangsu Aosaikang Pharmaceutical Co., Ltd.

Unknown

A Clinical Trial to Evaluate the Safety and Tolerability of Dexlansoprazole Injection in Healthy Chinese Adults（Part 2）

Safety Issues | Effect of Drugs

China
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, South Africa, Canada, Peru, New Zealand, Australia, Lithuania, Slovakia, Hungary, Latvia, Germany, Czech Republic
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR Compared to Placebo on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Canada, Czech Republic, Lithuania, Slovakia, Latvia, Estonia, Australia
Takeda

Completed

A Study to Evaluate the Pharmacokinetics of Dexlansoprazole 30 Milligram (mg) and 60 mg Delayed-release Capsules in Healthy Chinese Participants

Healthy Volunteers

China
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR on Maintaining Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Gastroesophageal Reflux Disease

Gastroesophageal Reflux Disease

United States
Advanced Center for Specialty Care
Takeda

Unknown

Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy

Laryngopharyngeal Reflux | Hypertrophy of Lingual Tonsil

United States
Takeda

Completed

Safety and Efficacy of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B

Gastroesophageal Reflux Disease
Takeda

Completed

Efficacy and Safety of Dexlansoprazole MR and Lansoprazole on Healing of Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States, Poland, Bulgaria, India, Canada, Peru, Russian Federation, Australia, New Zealand, Czech Republic, Slovakia, South Africa, Latvia, Lithuania, Colombia, Germany
Takeda

Completed

Efficacy and Safety of Dexlansoprazole Modified Release Formulation to Treat Heartburn

Gastroesophageal Reflux Disease

United States
Korea University Anam Hospital

Completed

Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients (MECCA)

Angina, Stable
Chinese PLA General Hospital

Unknown

Genotyping Guided Individualized Treatment of Clopidogrel and Ticagrelor in ACS (GI-CT)

CLOPIDOGREL, POOR METABOLISM of (Disorder)

China
Ospedale San Donato

Completed

Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction (Load & Go)

Acute Myocardial Infarction

Italy
Takeda

Completed

Efficacy of Dexlansoprazole MR on Heartburn Control in Participants Previously Receiving Twice Daily Proton Pump Inhibitor Therapy

Gastroesophageal Reflux

United States
Ramathibodi Hospital

Completed

Once Daily Dose Dexlansoprazole Quadruple Therapy for Helicobacter Pylori

H Pylori Eradication

Thailand
University of Pecs

Terminated

Doubling the Maintenance Dose of Clopidogrel in Patients With High On-Clopidogrel Platelet Reactivity (DOSER)

Stable Angina Pectoris | Ad Hoc Percutaneous Coronary Intervention

Hungary
Takeda

Completed

Comparison of Dexlansoprazole MR to Placebo on the Ability to Maintain Healing in Subjects With Healed Erosive Esophagitis

Esophagitis, Peptic | Esophagitis, Reflux

United States
Hospital Central San Luis Potosi, Mexico

Unknown

Patent Versus Generic Clopidogrel in Acute Coronary Syndrome

Acute Coronary Syndrome
Frankel, Amylynne, M.D.
Stiefel, a GSK Company

Unknown

Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects?

Psoriasis

United States
Lady Reading Hospital, Pakistan
Pakistan Chest Society, Pakistan

Recruiting

Clopidogrel for the Prevention of Exacerbations in Severe COPD (CLOPEX)

COPD | COPD Exacerbation Acute

Pakistan
Deutsches Herzzentrum Muenchen

Terminated

Abrupt Versus Tapered Interruption of Chronic Clopidogrel Therapy After DES Implantation (ISAR-CAUTION)

Coronary Artery Disease

Germany
Ascopharm Groupe Novasco
Groupe Hospitalier Pitie-Salpetriere; Medco Health Solutions, Inc.

Completed

Double the Dose of Clopidogrel or Switch to Prasugrel to Antagonize Proton Pump Inhibitor Interaction. (DOSAPI)

Anti Platelet Effects

France
University of North Carolina, Chapel Hill

Completed

Clopidogrel Pharmacogenomics Project

Disease Susceptibility

United States
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Effectiveness of Clopidogrel Resinate in PCI(PRIDE)

Coronary Artery Disease

Korea, Republic of
University of Pecs
Hungarian Academy of Sciences; KRKA

Completed

Comparison of Generic and Original Formulation of Clopidogrel (DOSER-GENERIC)

Coronary Heart Disease | Percutaneous Coronary Intervention
Sir Run Run Shaw Hospital

Unknown

Effect of Different Anti-platelet Strategies on the Long-term Outcome After Sirolimus Drug-eluting Stent Implantation (EASTS)

Coronary Artery Disease
Asan Medical Center

Completed

Helicobacter Pylori and Proton Pump Inhibitor

Helicobacter Infections

Korea, Republic of
Ajou University School of Medicine
Dong-A Pharmaceutical

Completed

Point-of-Care Measurements of Platelet Inhibition After Clopidogrel Loading in Patients With Acute Coronary Syndrome: Comparison of Generic Clopidogrel Bisulfate (Plavitor®) With Original Clopidogrel Bisulfate (Plavix®)

Acute Coronary Syndrome

Korea, Republic of
HK inno.N Corporation

Completed

Pharmacodynamic Properties of CJ-12420 on Evening Dosing

Healthy

Korea, Republic of
The Third Xiangya Hospital of Central South University

Completed

Study on the Registration of Coronary Heart Disease Patients Undergoing PCI

Coronary Heart Disease

China
Centre Hospitalier Universitaire de Saint Etienne

Completed

Investigation of Drug-drug Interaction Between Clopidogrel and Fluoxetine (PLATINE)

Healthy

France

3

Subscribe